Vir Biotechnology, Inc.
Vir Biotechnology, Inc. is listed today as Vir Biotechnology, Inc.: market value, financials and filings are on its company page.
Funding rounds
1 counted as startup funding, 2 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| May 2020 | $32 M | Private placement after listing | $10 to $50 million | equity | SEC | |
| Apr 2020 | $250 M | Private placement after listing | $250 million to $1 billion | equity | SEC | |
| Jun 2018 | $66 M | No. 1 | $50 to $250 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
As the listed company Vir Biotechnology, Inc., its revenue in fiscal 2025 came from these product and service lines: License and collaboration revenue $63.13 million (92%), Other revenue $3.39 million (5%), Grant revenue $2.04 million (3%).
Annual report (SEC XBRL) · Dec 2025
Vir Biotechnology, Inc. chose not to state its revenue in its newest notice of a funding round (May 2020).
SEC Form D · May 2020
The industry group it chose in its notices: Biotechnology.
SEC Form D · May 2020
Products and services#
No products or services of Vir Biotechnology, Inc. are on record.
Investors#
20 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Abu Dhabi Investment Authority | Fund or asset manager | not stated | not stated | Held Series A-1 and B preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Alaska Permanent Fund Corp | Fund or asset manager | not stated | not stated | Held Series A-1 and B preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| ARCH Venture Fund IX, L.P. | Venture capital | not stated | not stated | Held Series A-1 and B preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| ARCH Venture Fund IX Overage, L.P. | Venture capital | not stated | not stated | Held Series A-1 and B preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| ARCH Venture Partners IX, LLC | Venture capital | not stated | not stated | Held Series A-1 and B preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| ARCH Venture Partners IX, L.P. | Venture capital | not stated | not stated | Held Series A-1 and B preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| ARCH Venture Partners IX Overage, L.P. | Venture capital | not stated | not stated | Held Series A-1 and B preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Bill & Melinda Gates Foundation | Other | not stated | not stated | Held Series A-1 and B preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Fullerton Management Pte Ltd | Fund or asset manager | not stated | not stated | Held Series A-1 and B preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Philip A. Sharp | Person | not stated | not stated | Held Series A-1 preferred stock, director (Form 3, 2019) | SEC Form 3 |
| Platinum Falcon B 2018 RSC Ltd | Company | not stated | not stated | Held Series A-1 and B preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Platinum International Investment Holding RSC Ltd | Fund or asset manager | not stated | not stated | Held Series A-1 and B preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Q-Ventures Program II (Co-Invest Holdings) Ltd. | Venture capital | not stated | not stated | Held Series A-1 and B preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Robert J. More | Person | not stated | not stated | Held Series A-2 preferred stock, director (Form 3, 2019) | SEC Form 3 |
| SB Investment Advisers (UK) LTD | Fund or asset manager | not stated | not stated | Held Series A-1 and B preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Softbank Vision Fund (aiv M1) L.P. | Fund or asset manager | not stated | not stated | Held Series A-1 and B preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| SVF Endurance (Cayman) Ltd | Company | not stated | not stated | Held Series A-1 and B preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Temasek Holdings (Private) Ltd | Fund or asset manager | not stated | not stated | Held Series A-1 and B preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Temasek Life Sciences Private Ltd | Company | not stated | not stated | Held Series A-1 and B preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| TLS Beta Pte. Ltd. | Company | not stated | not stated | Held Series A-1 and B preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 5 investors.
Largest shareholders today
Institutions holding Vir Biotechnology, Inc. shares, as of Sep 30, 2026.
- BlackRock, Inc.$251 M13.11%
- ARCH Venture Management, LLC$142 M7.41%
- Vanguard Portfolio Management LLC$134 M7.02%
- SB Investment Advisers (UK) LTD$122 M6.39%
- GSK plc$96 M4.99%
- State Street Corp$87 M4.57%
- Point72 Asset Management, L.P.$76 M3.95%
- Vanguard Capital Management LLC$72 M3.77%
- Dimensional Fund Advisors LP$37 M1.94%
- Geode Capital Management, LLC$34 M1.76%
- MPM Bioimpact LLC$31 M1.64%
- Nuveen, LLC$25 M1.30%
- ADAR1 Capital Management, LLC$24 M1.26%
- Saturn V Capital Management LP$23 M1.19%
- Pictet Asset Management Holding SA$21 M1.11%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| George Scangos | Executive officer | May 2020 |
| Herbert Virgin | Executive officer | May 2020 |
| Howard Horn | Executive officer | May 2020 |
| Jay Parrish | Executive officer | May 2020 |
| Kristina Burow | Executive officer | May 2020 |
| Michael Kamarck | Executive officer | May 2020 |
| Phillip Pang | Executive officer | May 2020 |
| Alex Bangs | Executive officer | Jun 2018 |
| Alpna Seth | Executive officer | Jun 2018 |
| Dipchand Nishar | Director | May 2020 |
| George Scangos | Director | May 2020 |
| Phillip Sharp | Director | May 2020 |
| Robert More | Director | May 2020 |
| Robert Nelsen | Director | May 2020 |
| Robert Perez | Director | May 2020 |
| Saira Ramasastry | Director | May 2020 |
| Vicki Sato | Director | May 2020 |
| Klaus Frueh | Director | Jun 2018 |
| Kristina Burow | Director | Jun 2018 |
| Philip Sharp | Director | Jun 2018 |
| Thomas Daniel | Director | Jun 2018 |
About
Biotech company.
Went public since 2019. Its SEC number is that of a company listed on a stock exchange.